Skip to content

Project Aura: Home Trial of a Home-based Monitoring Service

Project Aura: Data Collection for a Home Monitoring Solution for Patients With Anaemia to Evaluate Delivery of Treatment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04137315
Enrollment
10
Registered
2019-10-24
Start date
2020-02-14
Completion date
2021-01-29
Last updated
2021-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Brief summary

This is a data collection study to compare diagnostic methods of a prototype of a home monitoring device against laboratory testing in the hospital.

Detailed description

The device/monitoring system being developed measures the haemoglobin and haematocrit levels in blood from a single drop of blood. By measuring these blood parameters, participants are able to monitor their haemoglobin level at home. The use of the device will take place in the participant's home to simulate what the investigators believe will be the ideal location for people who would prefer to self-manage their condition. This study is a data collection study to evaluate the performance of the prototype.

Interventions

Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.

Sponsors

Entia Ltd
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years of age. * Adequate english to participate in training sessions and use the analyser. * Patients of the study site who are currently undergoing treatment for anaemia of CKD with ESAs. * Patients who are not pregnant. * Patients who do not have a bleeding disorder. * Patients willing to perform self-tests 2-3 times a week. * Patients capable of providing informed consent before attending training. * Patients or patients with a carer capable of fine manipulation of the device and its consumables. * Patients or patients with a carer who own a smartphone which can download the app related to this study. * Patients or patients with carers who do not have eyesight limitations to be able to read the instructions on the screen of the prototype device. * Patients who are not expected to have to start dialysis treatment during the course of this study.

Exclusion criteria

* Does not have adequate English to participate in training or use the analyser without an interpreter. * Patients of the study site who are not currently undergoing anaemia treatment with ESAs. * Patients of the study site not willing to perform self-tests 2-3 times a week. * Patients of the study site not capable of providing consent or have a suitable, legally acceptable representative present to provide consent before the trial. * Patients who are pregnant. * Patients with a bleeding disorder. * Patients or their nominated carers who are not capable of fine manipulation of the device and its consumables. * Neither patients or their nominated carers do not own a smartphone which can install the app related to this study. * Patients or their nominated carers with eyesight limitations to not be able to read the instructions on the screen of the prototype device. * Patients who are expected to start dialysis treatment during the study.

Design outcomes

Primary

MeasureTime frameDescription
Quantitative capture of measurement system6 monthsData collection for evaluation of measurement system

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026